803 results about "Galactosucrose" patented technology

An improved process for chlorination of sugars produces chlorodeoxy derivatives, in particular the chlorination of sucrose-6-esters to produce sucralose (4,1′,6′-trichloro-4,1′,6′-trideoxy galactosucrose), with thionyl chloride and N,N-dimethyl formamide (DMF) at the ration of about 1 molar equivalent of thionyl chloride for every molar equivalent of free hydroxyl group.

The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.

A feed additive composition comprising a direct fed microbial (DFM), in combination with a xylanase (e.g. endo-1,4-β-d-xylanase) and a β-glucanase (and optionally a further fibre degrading enzyme), wherein the DFM is selected from the group consisting of an enzyme producing strain; a C5 sugar-fermenting strain; a short-chain fatty acid-producing strain; a fibrolytic, endogenous microflora-promoting strain; or combinations thereof. The DFM may be selected from the group consisting of: Bacillus subtilis AGTP BS3BP5, Bacillus subtilis AGTP BS442, B. subtilis AGTP BS521, B. subtilis AGTP BS918, Bacillus subtilis AGTP BS1013, B. subtilis AGTP BS1069, B. subtilis AGTP 944, B. pumilus AGTP BS 1068 or B. pumilus KX11-1, Enterococcus faecium ID7, Propionibacterium acidipropionici P169, Lactobacillus rhamnosus CNCM-1-3698, Lactobacillus farciminis CNCM-1-3699, a strain having all the characteristics thereof, any derivative or variant thereof, and combinations thereof and the further fibre degrading enzyme may be selected from the group consisting of a cellobiohydrolase (E.C. 3.2.1.176 and E.C. 3.2.1.91), a β-glucosidase (E.C. 3.2.1.21), a β-xylosidase (E.C. 3.2.1.37), a feruloyl esterase (E.C. 3.1.1.73), an α-arabinofuranosidase (E.C. 3.2.1.55), a pectinase (e.g. an endopolygalacturonase (E.C. 3.2.1.15), an exopolygalacturonase (E.C. 3.2.1.67) or a pectate lyase (E.C. 4.2.2.2)), or combinations thereof.

The invention relates to a colloid bismuth pectin compound and a quality control method of pharmaceutical compositions of the colloid bismuth pectin compound, and specifically provides a colloid bismuth pectin compound, new quality control indexes of pharmaceutical compositions of the colloid bismuth pectin compound and a detection method of the colloid bismuth pectin compound and the pharmaceutical compositions of the colloid bismuth. In the prior art, the quality of products having poor efficacy can not be well controlled because the efficacy-related indexes are not controlled strictly in the existing quality control methods of colloid bismuth pectin and pharmaceuticals thereof. Based on the existing quality control methods of colloid bismuth pectin and pharmaceuticals thereof, the following detection items and indexes are added: intrinsic viscosity, gel property, uniformity and galacturonic acid content. The invention can effectively ensure clinical efficacy of products, make the product quality standards more scientific, reasonable and controllable, and has great significance in quality control of the colloid bismuth pectin and the pharmaceutical preparation of colloid bismuth pectin.

The invention relates to a bactericide composition containing oligosaccharide and copper. The composition is characterized by being prepared from main active ingredients such as oligosaccharide and a copper preparation and pesticide auxiliaries and comprising the following components in percentage by weight: 1-45% of oligosaccharide, 1-50% of copper preparation and the balance of pesticide auxiliaries, wherein the oligosaccharide is one of amino-oligosaccharin (chitosan oligosaccharide), oligogalacturonide acid (pectic oligosaccharide, oligosaccharin) and sodium alginate oligosaccharide; the copper preparation is an inorganic copper or organic copper bactericide; and the dosage form of the bactericide composition can be water agents, emulsion in water, wettable powder, water dispersible granules, suspensions, granules, paste or microcapsule sustained-release agents. The composition has the following beneficial effects: the drug resistance of crops is overcome and delayed; the disease resistance of the crops is improved; the composition can generate synergy together with chemical bactericides; and the composition is safe in application and is safe to the environment and people.

The invention discloses two types of flavonoid glycoside compounds which are kaempferol-3-O-[alpha-L-rhamnopyranosyl-(1-3)-(2'' ', 4'' '-O-diacetyl-alpha-L-rhamnopyranosyl)-(1-6)]-beta-glucopyrose galactopyranoside and kaempferol-3-O-[alpha-L-rhamnopyranosyl-(1-3)-(4'' '-O-acetyl-alpha-L-rhamnopyranosyl)-(1-6)]-beta-D-glucopyrose galactopyranoside respectively. The invention also discloses a method for preparing the two types of flavonoid glycoside compounds. Moreover, pharmacological tests prove that the two types of flavonoid glycoside compounds have quite good effects of reducing blood sugar and blood fat and resisting oxidation and cerebral ischemia, and thus, the flavonoid glycoside compounds of the invention can be used for preparing medicaments, food and cosmetics for preventing and treating diabetes, reducing blood fat and resisting oxidation and cerebral ischemia.

The invention relates to a new application of low molecular citrus pectin, in particular to the application of low molecular citrus pectin for treating and preventing lead and heavy metal poisoning in prepared medicines, foods and health care products. The low molecular citrus pectin is a compound prepared from soluble dietary fiber and galacturonic acid, the polysaccharide derivative is used as a metal ion absorbent (chelating agent), has absorption action on heavy metal ions, can remove heavy ions, such as Zn2+, Cu2+, Cd2+, Ag+, Cr3+, Ni2+, Hg2+, Pb2+ and the like. The low molecular citrus pectin is different from common chemical chelating agents; proved by animal and clinic experiments, lead, mercury and arsenic are discharged out of human bodies during toxin discharge, and the key level of calcium, magnesium, zinc or other minerals can not be influenced. The natural chelating function of the low molecular citrus pectin is a most ideal and successful solution for heavy metal pollution in the human body at present. Thus, the low molecular citrus pectin has the function of preventing various diseases and especially has special functions of clearing away harmful cells and discharging toxins in the human body.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+/-0.3): (1+/-0.3): (3.5+/-0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and/or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and/or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

The invention discloses a method for improving yield of salvianolic acid B in savia miltiorrhiza suspension culture cells by inducing, specifically comprising the following steps: 1) cultivating the aseptic seedlings; 2) inducing the callus; 3) sub-cultivating the callus; 4) cultivating the callus by suspending; 5) inducing to produce the salvianolic acid B; and 6) harvesting the culture cells. The method solves the problem that the salvianolic acid B is not produced after the inducing factors, such as yeast extract, galacturonic acid, mycelia extract and the like are added. The content of the salvianolic acid B in the savia miltiorrhiza suspension culture cells is increased by about 5 times by using the method. The technology condition provided by the invention is suitable for industrial production of the salvianolic acid B on a large scale by a cell culture method after being expanded.

The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3.GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.

The invention discloses a micro-ecological composition for improving constipation by targeting intestinal flora and a preparation of the micro-ecological composition. The micro-ecological compositioncomprises probiotics, prebiotics and medicinal and edible traditional Chinese medicines, wherein the probiotics are selected from at least one of bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans; the prebiotics are selected from at least one of stachyose, fructo-oligosaccharide, isomalto-oligosaccharide, galacto-oligosaccharide, inulin, resistant dextrin and xylooligosaccharide; and the medicinal and edible traditional Chinese medicines are selected from at least one of semen sesami nigri, semen cassiae, fructus cannabis, honey, semen lablab album, semen coicis, poria cocos and lotus leaves. The micro-ecological composition can effectively regulate intestinal tract micro-ecology in a targeted mode, and finally the purpose of improving constipation is achieved.

Methods for providing transgenic plants and parts hereof that, relative to the wild type state, is modified in a complex cell wall polysaccharide structure including pectins and hemicelluloses, the modification being in the overall glycosidic linkage pattern or the monosaccharide profile, comprising transforming a plant cell with a nucleotide sequence that causes an altered production of a complex cell wall polysaccharide-modifying enzyme such as endo-rhamnogalacturonan hydrolase, an endo-rhamnogalacturonan lyase, an endo-galactanase, an endo-arabinanase, an arabinofuranosidase, a galactosidase such as a beta-galactosidase, a xylosidase and an exo-galacturosidase. The modification can occur in vivo or post harvest, in which latter case the modifying enzyme is separated in the growing plant from its substrate, e.g. by targeting the enzyme to the Golgi, the endoplasmic reticulum or a vacuole, or is in a form that is inactive in the plant. After harvest the enzyme is brought into contact with its substrate or it is activated to provide the desired post harvest modification of the cell wall polysaccharide. The transgenic plant materials have improved functionalities and are useful in food and feed manufacturing and as pharmaceutically or medically active substances.

Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:

The present invention relates to skin care compositions providing a method of enhancing the remodeling of age damaged and sun damaged skin in mammals utilizing an elastin peptide (EP) ligand of the general formula (GXXPG)n and in particular the sequences of (VGVAPG)n and/or (GVAPGV)n, and/or (VAPGVG)n and/or (APGVGV)n and/or (PGVGVA)n and/or (GVGVAP)n and a galactosugar which modulates the effect of the elastin peptide ligand(EP) on its lectin the Elastin-Binding Receptor (EBR). wherin A is a peptide-forming residue of L-alanine; G is a peptide-forming residue of glycine P is a peptide-forming residue of L-proline V is a peptide-forming residue of L-valine X is a peptide-forming residue of a single unspecified amino acid

Peptide representations in this application conform to the standard practice of writing the NH₂-terminal amino acid residue at the left of the formula and the CO₂ H-terminal amino

acid residue at the right.

The invention discloses a composition for improving the intestinal microecology and preventing a chronic disease. The composition is prepared from inulin, galactooligosaccharide and composite dietary fiber, wherein the ratio of the inulin to the galactooligosaccharide to the composite dietary fiber is (1 to 75) to (1 to 75) to (5 to 95), and preferably (10 to 50) to (10 to 50) to (25 to 50). The invention further discloses balanced nutrition food containing the composition. The balanced nutrition food comprises cereal meal; and the ratio of the cereal meal to the composition is (50 to 95) to (50 to 5), and preferably (70 to 95) to (30 to 5). The composition can retain moderate survival of non probiotics through common glycan; a functional glycan prebiotics combination can promote growth of probiotics; and by the synergistic effect among glycans, stable equilibrium of intestinal microorganisms can be maintained, the intestinal flux, endotoxins and inflammatory factors are reduced, the immunity is enhanced, and the chronic disease is prevented. The balanced nutrition food can provide balanced nutrition for superorganisms, improve the subhealth and prevent the chronic disease.

The invention discloses a chromogenic medium used for detecting esherichia coli O157:H7. The medium comprises agar, peptone, beef extract powder, sodium chloride, sorbitol, inositol, neutral red, beta-galactosidase chromogenic substrate, beta-glucuronidase chromogenic substrate, isopropyl-beta-D- thiogalactopyranoside, natrium taurocholicum, potassium tellurite and cefixime. The chromogenic medium used for detecting esherichia coli O157:H7 of the present invention has the advantages of high sensitivity, good specificity, direct bacterial strain discrimination according to colony color, short detection period and strong operationality, is suitable for treating high-reflux samples, is capable of comprehensively, systematically and accurately detecting and preliminarily identifying the esherichia coli O157:H7 in food production and environment, and provides a novel approach for rapidly detecting the microbes.

The invention relates to the field of medicines related to diabetes. More specifically, the invention relates to a sodium galactose transporter type 2 (SGLT2) inhibitor having a structure of C-glucoside derivatives containing saturated six-membered ring, a preparation method thereof, a pharmaceutical composition containing the derivatives and application of the derivatives in preparing diabetes medicines, wherein X and Y are defined as the followings: (1) X = Y = carbon atom; (2) X = Y = nitrogen atom; (3) X = nitrogen atom and Y = oxide atom; and (4) X = nitrogen atom and Y = carbon atom. Other groups are defined as specification.

The invention belongs to the technical field of analysis and detection, and discloses a fluorescence probe for detecting beta-galactosidase as well as a preparation method and application of the fluorescence probe. The substrate of the fluorescence probe is 2-(2-(dimethylamino)ethyl-6-(((3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxidation)-1H-benzisoquinoline diketone, and has a structural formula shown in the description. The fluorescence probe has the advantages that naphthalic anhydride is taken as a fluorophore of the substrate of the fluorescence probe, and lined with a galactose group which can respond to the specificity of beta-galactosidase; the ratio of double fluorescence signals being I554/I445 is taken as a detection signal, and thus the detection accuracy is higher; under the condition of 1U/L enzyme concentration, obvious fluorescence alteration can be detected, and the lower detection limit is 0.35 U/L; the fluorescence probe is excited (418 nm) in a visible light region, so that the background interference can be eliminated to achieve a better detection effect.

The invention discloses a method to prepare engineering bacteria of 5-glycyl propionic acid and methods for using them, which comprises the following steps: incorporating radial agrobacteriocin; setting the preserved number at CGMCC No. 1938; activating engineering bacteria with LB medium flat; getting monoclonal of the engineering bacteria; seeding to shake; culturing; getting first-grade seed; seeding the first-grade in shake; culturing; getting second-grade seed; seeding the second-grade seed in fermenter; culturing; cooling and evoking with isopropyl-beta-D-sulfo-galactose-glycoside; culturing continually; proceeding supplementing material culture. This engineering bacteria possesses higher ALA synthase expression, simple craft, low cost and good industrial prospect.

The invention provides a composition for adjusting intestinal microecology of a human body. The composition comprises stachyose and galactooligosaccharides as active ingredients. The composition provided by the invention can be used for effectively adjusting the intestinal bacteria community function.

The invention relates to the field of processing of infant foods, and particularly relates to baby nutrition noodles and a preparation method of the baby nutrition noodles. The preparation method takes excellent wheatmeal and concentrated whey protein powder as main materials, fully improves the utilization rate and nutrition value of protein, and strengthens fructo-oligose, galactooligosaccharide, vitamine and mineral substance at the same, wherein the ratio of amino acid is very close to that needed by the human body. The low-temperature moisturizing drying process is adopted to produce the high-quality baby nutrition noodles suitable for eating of infants.